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EDITORIAL
Evolution of infrapopliteal artery stenting
Evolução dos implantes de stents em artérias infrapoplíteas
Nelson Wolosker*
Over the last 20 years, vascular surgeons have wit-
nessed great evolution of the therapy for infrapopliteal
artery obstructive disease.
In the 1970s, patients with obstruc-
tive disease of tibial arteries did not
have any possibilities for revasculariza-
tion and had to undergo alternative
procedures, such as sympathectomy,
neurotripsy or even amputation.
In the 1980s, the introduction of
distal bypasses revolutionized vascu-
lar surgery and a great number of patients were ben-
efited through restoration of the blood flow for treating
wound healing and/or critical ischemia.1
With the recent advances in image acquisition sys-
tems and instruments, endovascular procedures that in
the 1980s and 1990s were restricted to the treatment of
small segmental lesions of iliac arteries (today classified
as TASC A) started to be used in the femoropopliteal
segment at the beginning of this new millennium.2
The use of short catheters and stents specially
designed for coronaries has given rise to encouraging
results in treating obstructive lesions of infragenicular
arteries, which has stimulated research and develop-
ment of appropriate equipment for these arteries to
replace adapted equipment. The first generation of dis-
tal instruments was 5 to 8 cm angioplasty balloons with
low compliance, over-the-wire system and high resis-
tance for 0.014 guide-wires. Today, balloons of up to 15
cm in length are available for 0.035 guide-wires which
facilitate the procedures and
improve the immediate results from
angioplasty of the tibial arteries.3
Stents have been improved and
have been producing even better
results, as can be seen in the study
by Bosiers et al.4 Their paper pro-
vides an extensive review of the lit-
erature and results of five types of stents. The baremetal
stents are bare metal balloon-expandable stents made
with Cobalt
Chromiumalloywith high radial strength, good fluo-
roscopic visibility and available in up to 78 mm lengths.
To inhibit the intimal hyperplasia, there were designed
passive coated balloon-expandable stents and drug-
eluting balloon-expandable stents. To avoid stent frac-
tures frequently observed in superficial femoral artery
stents, self-expanding nitinol stents were designed.
Finally, to avoid permanent presence of an artificial
implant, absorbable stents developed in biocompatible
materials that completely degrade after some months.
This paper provides an extensive review of the litera-
ture and results of these five types of stents. All these
options are presented alongwith the initial results, which
are indeed good and stimulating.
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Currently, in our group headed by Prof. Pedro Puech-
Leão, the first-choice therapy for peripheral obstructive
lesions is endovascular surgery. The use of stents in tibial
arteries is an essential complement for obtaining better
rates of limb salvage.
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